PLYMOUTH, Mich.--(BUSINESS WIRE)--
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage
biopharmaceutical company focused on developing and commercializing
first-in-class, oral, low-density lipoprotein cholesterol (LDL-C)
lowering therapies for the treatment of hypercholesterolemia, today
announced that Roger S. Newton, Ph.D., Esperion's executive
chairman, chief scientific officer and company founder, will present at
the Stifel Nicolaus 2013 Healthcare Conference in Boston. Dr. Newton's
presentation will take place on Wednesday, September 11, at 3:50 p.m. ET
at the Four Seasons Hotel.
To hear the live audio webcast and view the slides of the Esperion
presentation, please visit http://www.veracast.com/webcasts/stifel/healthcare2013/28113409462.cfm.
A replay of the webcast will be available on the company's website for
30 days following the live event.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a biopharmaceutical company focused on
the research, development and commercialization of therapies for the
treatment of patients with elevated levels of low-density lipoprotein
cholesterol (LDL-C) and other cardiometabolic risk factors. ETC-1002,
Esperion's lead product candidate, is a unique, first-in-class, orally
available, once-daily small molecule designed to lower levels of LDL-C
and to avoid side effects associated with existing LDL-C lowering
therapies. ETC-1002 is targeted for statin intolerant patients with
elevated levels of LDL-C. Esperion has completed seven clinical studies
to date, including four Phase 2a studies, and expects to initiate a
robust Phase 2b clinical program in the fourth quarter of 2013. For more
information, please visit www.esperion.com.
BrewLife
Denise Powell, 510-703-9491
dpowell@brewlife.com
Source: Esperion Therapeutics
News Provided by Acquire Media